194 related articles for article (PubMed ID: 21277626)
21. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
22. [Grazax--treatment for grass pollen hay fever].
Svendsen UG
Ugeskr Laeger; 2008 Jan; 170(3):135-7. PubMed ID: 18208728
[TBL] [Abstract][Full Text] [Related]
23. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
24. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population.
Linneberg A; Bødtger U
Allergy; 2007 Jul; 62(7):825-6. PubMed ID: 17573735
[No Abstract] [Full Text] [Related]
25. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
[TBL] [Abstract][Full Text] [Related]
26. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
27. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study.
Zidarn M; Košnik M; Šilar M; Bajrović N; Korošec P
Allergy; 2015 May; 70(5):547-55. PubMed ID: 25627309
[TBL] [Abstract][Full Text] [Related]
28. Oralair®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis.
Hong J; Bielory L
Expert Rev Clin Immunol; 2011 Jul; 7(4):437-44. PubMed ID: 21790286
[TBL] [Abstract][Full Text] [Related]
29. Grass pollen specific sublingual/swallow immunotherapy in children: open-controlled comparison among different treatment protocols.
Di Rienzo V; Puccinelli P; Frati F; Parmiani S
Allergol Immunopathol (Madr); 1999; 27(3):145-51. PubMed ID: 10431100
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependence of sublingual immunotherapy shown by meta-analysis.
Frati F; Incorvaia C; Scurati S; Sensi L; Marcucci F
J Allergy Clin Immunol; 2011 Apr; 127(4):1076-7; author reply 1077-8. PubMed ID: 21306764
[No Abstract] [Full Text] [Related]
31. Serum transforming growth factor-beta levels depend on allergen exposure in allergic rhinitis.
Ciprandi G; De Amici M; Tosca M; Marseglia G
Int Arch Allergy Immunol; 2010; 152(1):66-70. PubMed ID: 19940507
[TBL] [Abstract][Full Text] [Related]
32. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates.
Sieber J; De Geest S; Shah-Hosseini K; Mösges R
Curr Med Res Opin; 2011 Apr; 27(4):855-61. PubMed ID: 21323505
[TBL] [Abstract][Full Text] [Related]
33. Anaphylaxis caused by allergen sublingual immunotherapy?
André C; Fadel R
Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
[No Abstract] [Full Text] [Related]
34. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
35. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine.
Moingeon P; Hrabina M; Bergmann KC; Jaeger S; Frati F; Bordas V; Peltre G
Int Arch Allergy Immunol; 2008; 146(4):338-42. PubMed ID: 18362477
[TBL] [Abstract][Full Text] [Related]
36. Grazax: an oral vaccine for the treatment of grass pollen allergy (hay fever).
Allison C; Fraser J
Issues Emerg Health Technol; 2007 Nov; (107):1-4. PubMed ID: 18041171
[TBL] [Abstract][Full Text] [Related]
37. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.
Nouri-Aria KT; Pilette C; Jacobson MR; Watanabe H; Durham SR
J Allergy Clin Immunol; 2005 Jul; 116(1):73-9. PubMed ID: 15990777
[TBL] [Abstract][Full Text] [Related]
38. Development of a sublingual allergy vaccine for grass pollinosis.
Frati F; Scurati S; Puccinelli P; David M; Hilaire C; Capecce M; Marcucci F; Incorvaia C
Drug Des Devel Ther; 2010 Jul; 4():99-105. PubMed ID: 20689696
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
40. Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study.
Allam JP; Wuestenberg E; Wolf H; Klimek L; Decot E; Horn A; Schnitker J; Bieber T; Novak N
J Allergy Clin Immunol; 2014 Jun; 133(6):1757-9.e3. PubMed ID: 24794686
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
